Research compound supplied in Australia by Pulse Biolabs for laboratory use. Available in 5mg.
The body’s own growth hormone-releasing hormone survives minutes in the blood. CJC-1295 was engineered to send the same signal for days, and the two versions sold under the name differ in exactly that.
CJC-1295 without DAC, also called modified GRF(1–29), is the enzyme-resistant backbone of CJC-1295 without the albumin-binding group. It carries the growth hormone-releasing hormone signal but clears quickly, producing a brief pulse rather than a sustained rise. The human trials published for CJC-1295 used the DAC form; no equivalent trials of this version exist, so its behaviour is inferred from the shared backbone and older GRF(1–29) work.
Read the full research note →| Presentation | Code | Status | Price |
|---|---|---|---|
| 5mg | CND5 | In stock | $65 |
No batch-specific test report is currently published for this product. What a report does and does not show.
Supplied as lyophilised (freeze-dried) powder in a sealed vial. Store sealed and protected from light at the conditions stated on the product label or supplied specification. Solvent choice, concentration and handling after reconstitution depend on the compound and on the laboratory’s own procedures, and are not specified here.
CJC-1295, with or without DAC, is not an approved medicine in Australia, and no approval elsewhere was identified. Growth hormone-releasing factors are prohibited at all times in sport under WADA category S2.
Status checked 2026-09-23. Details and sources in the research note.